AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm's fourth-quarter revenue exceeded ...

Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in 2023.